ABL Bio Inc. a clinical-stage biotech company developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, announced a wor...
AVITA Medical, Inc., a leading therapeutic acute wound care company delivering transformative solutions, announced the U.S. commercial launch of Cohealyx&t...
Novartis announced the US Food and Drug Administration (FDA) has granted accelerated approval for Vanrafia® (atrasentan), a potent and selective e...
Genentech, a member of the Roche Group, announced that the Phase III MUSETTE trial comparing a high dose of Ocrevus® (ocrelizumab) intraveno...
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment o...
Shanghai Yingli Pharmaceutical Co., Ltd., a clinical stage biotechnology company developing oral small molecule drugs for cancer, metabolic, and immune dis...
Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, will share data via two poster presentations at the ...
Inventiva ("Inventiva" or the "Company"), a clinical-focused biopharmaceutical company focused on the development of orally administered small molecule dru...
Franco Cavaleri, B.Sc., Ph.D.c, a distinguished biomedical research scientist and CEO of Biologic Pharmamedical Research and Manufacturing, has publis...
Hoth Therapeutics, Inc. , a patient-focused clinical-stage biopharmaceutical company, announced that it has received an official Filing Rec...
Abbisko Therapeutics Co., Ltd. announced that Merck has exercised the global commercialization option for pimicotinib (ABSK021), with an option exercise fe...
Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, announced moderated poster presentations of new data from the landmark HELIOS-B...
TARRYTOWN -- Regeneron Pharmaceuticals, and Sanofi announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan ...
Novartis announced that the US Food and Drug Administration (FDA) approved Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) for patients with pro...
© 2025 Biopharma Boardroom. All Rights Reserved.
